1-7 of 7
William Figg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Response-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, and Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Jillian Simard, James D Phelan, Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, Jagan R. Muppidi, Michail Lionakis, Cody J Peer, Amynah Pradhan, Matthias Holdhoff, Lode J. Swinnen, Kieron Dunleavy, Catherine Lai, Sami Ibrahimi, Michael Glantz, John A Butman, Kim Johnson, Seth M. Steinberg, William Figg, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2023) 142 (Supplement 1): 854.
https://doi.org/10.1182/blood-2023-177994
Published: 2023
Journal Articles

Preliminary Analysis of an Ongoing Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Rahul Lakhotia, Christopher Melani, Jagan R. Muppidi, Stefania Pittaluga, James D Phelan, Colleen Ramsower, Lisa M. Rimsza, Ryan S Robertorye, George Wright, Mark Meerson, Ekaterina Postovalova, Alexander Bagaev, Nathan Fowler, Liza Lindenberg, Esther Mena, Ethan Bergvall, Amynah Pradhan, Atekelt Tadese, Candis Morrison, Sarah Evans, Sumaya Berg, Seth M. Steinberg, William Figg, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2023) 142 (Supplement 1): 1676.
https://doi.org/10.1182/blood-2023-185038
Published: 2023
Journal Articles

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Elizabeth Hill, Joseph L. Roswarski, Amrit Bhaskarla, Alexander Dew, Candis Morrison, Michael Emanuel, Ani Petrosyan, Hao-Wei Wang, Constance M. Yuan, Liza Lindenberg, Esther Mena, Baris Turkbey, Nisha Patel, Irina Maric, Alina Dulau-Florea, Katherine Calvo, Raul C. Braylan, Maryalice Stetler-Stevenson, Seth M. Steinberg, William Figg, Ryan M. Young, Ola Landgren, Mark Roschewski, Dickran Kazandjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 337.
https://doi.org/10.1182/blood-2023-181811
Published: 2023
Journal Articles

Phase I Study of Response-Adapted Treatment with Venetoclax, Obinutuzumab, and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-Cell Malignancies

Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, James D Phelan, Amynah Pradhan, Atekelt Tadese, Candis Morrison, Sarah Evans, Seth M. Steinberg, William Figg, Elaine S Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2023) 142 (Supplement 1): 6172.
https://doi.org/10.1182/blood-2023-178766
Published: 2023
Journal Articles

A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up

Dickran Kazandjian, MD, Neha Korde, MD, Sham Mailankody, MBBS, Yong Zhang, PhD, Jennifer Hsu, RN, Elizabeth Hill, MD, Candis Morrison, CNP, PhD, Sneha Divakarla, MHA, Mary L. Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Pallavi Galera, Alina Dulau-Florea, MD, Dalia Salem, MD, Esther Gonzalez, MD, Liza Lindenberg, MD, Irina Maric, MD MSci, Katherine R. Calvo, MD PhD, Raul C. Braylan, MD, Constance Yuan, MD PhD, Wyndham H. Wilson, MD PhD, Peter Choyke, MD, Maryalice Stetler-Stevenson, MD PhD, Seth M. Steinberg, PhD, William Figg, PharmD, Mark Roschewski, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1957.
https://doi.org/10.1182/blood-2018-99-111712
Published: 2018
Journal Articles

Sustained High Rates of Complete Response and Minimal Residual Disease Negativity after 8 Cycles of Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R) in Patients with High-Risk Smoldering Multiple Myeloma: Updated Results of Clinical and Correlative Phase 2 Study

Dickran Kazandjian, MD, Neha S Korde, MD, Mark Roschewski, MD, Sham Mailankody, MD, Candis Morrison, RN, PhD, Elisabet E. Manasanch, MD, Mary L Kwok, MD, Nishant Tageja, MD, Manisha Bhutani, MD, Adriana Zingone, PhD, Rene Costello, Yong Zhang, PhD, Marcia Mulquin, Liz Lamping, Ashley Carpenter, Brenda Roberson, Irina Maric, MD, Katherine R. Calvo, MD PhD, Raul C Braylan, MD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C. Arthur, MD, Liza Lindenberg, Karen A. Kurdziel, MD, Peter Choyke, Seth M. Steinberg, PhD, William Figg, Wyndham H. Wilson, MD PhD, Ola Landgren, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3339.
https://doi.org/10.1182/blood.V128.22.3339.3339
Published: 2016
Journal Articles

Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study

Dickran Kazandjian, MD, Neha S Korde, MD, Mark Roschewski, MD, Sham Mailankody, MD, Candis Morrison, RN, PhD, Elisabet E. Manasanch, MD, Mary L Kwok, MD, Nishant Tageja, MD, Manisha Bhutani, MD, Adriana Zingone, PhD, Rene Costello, Yong Zhang, PhD, Marcia Mulquin, Liz Lamping, Ashley Carpenter, Brenda Roberson, Irina Maric, MD, Katherine R. Calvo, MD PhD, Raul C Braylan, MD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C. Arthur, MD, Liza Lindenberg, Karen A. Kurdziel, MD, Peter Choyke, Seth M. Steinberg, PhD, William Figg, Wyndham H. Wilson, MD PhD, Ola Landgren, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4527.
https://doi.org/10.1182/blood.V128.22.4527.4527
Published: 2016